- AIPAC reaches ~72% of events and TACTI-002 recruitment is progressing well
- New data from TACTI-002 and INSIGHT-004 to be reported at ASCO in June 2021
- TACTI-003 clinical trial design enables evaluation of efti in 1st line recurrent or metastatic HNSCC patients to better understand its effect in combination with pembrolizumab
- Robust financial position with cash runway into calendar year 2023, beyond several significant data read-outs
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, provides an update on its clinical and preclinical programs.
For more information, download the attached PDF.
Download this document
